Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Elective surgeries may be on hold for now, but this healthcare stock has a lot going for it.

Why Intuitive Surgical's Coronavirus Sell-off is an Incredible Buying Opportunity

There's arguably not a more attractive stock to buy right now.

Have $1,000? Here's My Single Best Investment Idea for April

Amazon

Alphabet

Block

U.S. Bancorp

The stock market sell-off has created an incredible opportunity to buy into these high-quality companies at a discount.

Smart Investors Will Be Buying These 5 Stocks in April

Bristol-Myers

Vertex Pharmaceuticals

Profitable. Great revenue and earnings growth.

My Top Healthcare Stocks to Buy in the Market Crash

Visa

A bear market is the perfect opportunity to go shopping for companies that can lead you to financial independence.

Coronavirus Crash: 4 Stocks to Buy to Secure Your Financial Future

Answering questions from callers, former hedge fund manager and CNBC “Mad Money” host Jim Cramer revealed his favorite stock picks Thursday.

Cramer Reveals Stock Favorites, Says Intuitive Surgical A 'Winner'

ABIOMED

Arista Networks

Incyte

IPG Photonics

Regeneron Pharmaceuticals

Skyworks Solutions

Given the near-term economic uncertainty surrounding the COVID-19 outbreak, investors have been shifting their focus from growth stocks to stocks that have the balance sheets and liquidity to weather the current downturn.

10 Stocks To Buy With Low Debt And High Liquidity

eBay

Edwards Lifesciences

JPMorgan Chase & Co

Pfizer

Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.

5 Superstar Stocks on Sale During the Coronavirus Crisis

Brookfield Infrastructure Partners L.P.

The market might take you for a roller-coaster ride, but these stocks will be long-term winners no matter what happens next.

3 Great Stocks to Buy Even If the Stock Market Plunges Again

Align Technology

Insulet

Investors are optimistic about a potential federal stimulus bill.

Why Align Technology, Insulet, and Intuitive Surgical Stocks Are Soaring Today

ISRG stock has skidded this year, leading Intuitive Surgical stock performance to lag its peers in its medical technology group. So, is it time to take on this robotic surgery stock?

This Robotic Surgery Behemoth Hit A Speed Bump — Is ISRG Stock A Buy?

Teladoc

Despite the current chaos in the stock market, these two healthcare stocks could be winners in the long run.

2 Healthcare Stocks to Buy in the Coronavirus Bear Market

Inuitive Surgical: Buying With Both Hands

F5 Networks

Johnson & Johnson

Microsoft

Jeff Reeves lists stocks that should be relatively safe as business conditions threaten some companies with bankruptcy

Jeff Reeves's Strength in Numbers: These are the five most financially sound companies amid a cash crunch

Intuitive Surgical stock has fared better than the broader markets through the current crisis, and it will likely bounce back strongly and potentially outperform the broader markets, when the crisis winds down. For perspective, the stock rose over 300% between March 2009 and January 2010.

Can Intuitive Surgical Stock Outperform The Broader S&P 500 After Coronavirus?

Alnylam Pharmaceuticals

ResMed

Three words: Coronavirus market meltdown.

Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today

Gilead Sciences

Three steps you can take to follow Warren Buffett's advice and achieve extraordinary long-term results.

How to Be Greedy When Others Are Fearful

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.

Here's Why You Should Invest in Intuitive Surgical Stock Now

Looking for great stocks to buy if the market rebounds in a big way? Think healthcare.

3 Top Healthcare Stocks to Buy in March

If competitive advantages are your thing, then this list of brand-name businesses is for you.

3 Top Stocks That Will Make You Richer in March (and Beyond)

Abbott Labs

Baxter

Boston Scientific

Hill-Rom Hlds

Medtronic

Perrigo

Stryker

Zimmer Biomet Hlds

Medical Products Industry Outlook: Growth Prospects Bright

There is an upside of over 6% for Intuitive Surgical’s stock, in our view. We estimate Intuitive Surgical’s fair price estimate to be around $652, based on expected EPS of $14.59 on an adjusted basis for full year 2020 and price to earnings multiple of 44.7x.

What’s The Upside For Intuitive Surgical’s Stock?

Which stock wins in a matchup between these healthcare juggernauts?

Better Buy: Intuitive Surgical vs. Johnson & Johnson

bluebird bio

It's not just their cancer treatments that make these stocks attractive.

3 Cancer Treatment Stocks  to Buy Right Now

The robotic surgery leader is facing potential headwinds but should continue making progress in 2020.

News for Intuitive Surgical Stock (ISRG)